Patricia Pereira dos Santos Melli

Prof. Patricia Pereira dos Santos Melli

gynecologist and obstetrician, Hospital das Clínicas, FMRP/USP, Ribeirão Prêto, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
ABAntonio Braga
Antonio Braga
RKRegis Kreitchmann
Regis Kreitchmann
MMMaria Luiza Bezerra Menezes
Maria Luiza Bezerra Menezes
AMAngélica Espinosa Barbosa Miranda
Angélica Espinosa Barbosa Miranda
MWMaria Celeste Osório Wender
Maria Celeste Osório Wender
Introduction Over the last few decades, Brazil has faced significant challenges related to infection by the dengue virus (DENV) transmitted by the Aedes aegypti mosquito. Dengue is endemic in many tropical and subtropical regions of the planet, often leading to epidemic outbreaks of varying intensity and frequency, influenced by factors such as rising temperatures, catastrophic […] Introduction Over the last few decades, Brazil has faced significant challenges related to infection by the dengue virus (DENV) transmitted by the Aedes aegypti mosquito. Dengue is endemic in many tropical and subtropical regions of the planet, often leading to epidemic outbreaks of varying intensity and frequency, influenced by factors such as rising temperatures, catastrophic […]

5 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JBJhohann Richard de Lima Benzi
Jhohann Richard de Lima Benzi
PMPatricia Pereira dos Santos Melli
Patricia Pereira dos Santos Melli
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
JUJashvant D Unadkat
Jashvant D Unadkat
VLVera Lucia Lanchote
Vera Lucia Lanchote
Inflammation can regulate hepatic drug metabolism enzymes and transporters. The impact of inflammation on renal drug transporters remains to be elucidated. We aimed to quantify the effect of inflammation (caused by acute pyelonephritis) on the in vivo activity of renal OAT1/3, using the probe drug furosemide. Pregnant women (second or third trimester) received a single oral dose of furosemide 40 mg during acute pyelonephritis (Phase 1; n = 7) and after its resolution (Phase 2; n = 7; by treatment with intravenous cefuroxime 750 mg TID for 3–7 days), separated by 10 to 14 days. The IL-6, IFN-γ, TNF-α, MCP-1, and C-reactive protein plasma concentrations were higher in Phase I vs. Phase II. The pregnant women had a lower geometric mean [CV%] furosemide CLsecretion (3.9 [43.4] vs. 6.7 [43.8] L/h) and formation clearance to the glucuronide (1.1 [85.9] vs. 2.3 [64.1] L/h) in Phase 1 vs. Phase 2. Inflammation reduced the in vivo activity of renal OAT1/3 (mediating furosemide CLsecretion) and UGT1A9/1A1 (mediating the formation of furosemide glucuronide) by approximately 40% and 54%, respectively, presumably by elevating the plasma cytokine concentrations. The dosing regimens of narrow therapeutic window OAT drug substrates may need to be adjusted during inflammatory conditions.

23 September 2024 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
PMPatricia Pereira dos Santos Melli
Patricia Pereira dos Santos Melli
AMAngélica Espinosa Miranda
Angélica Espinosa Miranda
HMHelaine Maria Besteti Pires Mayer Milanez
Helaine Maria Besteti Pires Mayer Milanez
MMMaria Luiza Menezes
Maria Luiza Menezes
RKRegis Kreitchmann
Regis Kreitchmann
Key points •Although congenital syphilis has a known etiological agent, accessible diagnosis and low-cost, effective treatment with low fetal toxicity, it continues to challenge obstetric and antenatal care services. •The increasing rates of syphilis in the general population have direct repercussions on the increase in cases of congenital syphilis, a situation of objective interest for […] Key points •Although congenital syphilis has a known etiological agent, accessible diagnosis and low-cost, effective treatment with low fetal toxicity, it continues to challenge obstetric and antenatal care services. •The increasing rates of syphilis in the general population have direct repercussions on the increase in cases of congenital syphilis, a situation of objective interest for […]

20 June 2023 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
Fernanda MoreiraFernanda Moreira
Fernanda Moreira
TPTiago Antunes Paz
Tiago Antunes Paz
PMPatricia Pereira dos Santos Melli
Patricia Pereira dos Santos Melli
MTMatheus de Lucca Thomaz
Matheus de Lucca Thomaz
MMMaria Paula Marques
Maria Paula Marques
VLVera Lucia Lanchote
Vera Lucia Lanchote

1 March 2018 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
APAna Teresa Mancini Pimenta
Ana Teresa Mancini Pimenta
ICIsadora Alonso Correa
Isadora Alonso Correa
PMPatricia Pereira dos Santos Melli
Patricia Pereira dos Santos Melli
RARenata Abduch
Renata Abduch
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
SQSilvana Maria Quintana
Silvana Maria Quintana
KEY WORDS: HIV-1; Pregnancy; Drug resistance

31 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JBJhohann Richard de Lima Benzi
Jhohann Richard de Lima Benzi
PMPatricia Pereira dos Santos Melli
Patricia Pereira dos Santos Melli
Geraldo DuarteGeraldo Duarte
Geraldo Duarte
JUJashvant D Unadkat
Jashvant D Unadkat
VLVera Lucia Lanchote
Vera Lucia Lanchote
Inflammation can regulate hepatic drug metabolism enzymes and transporters. The impact of inflammation on renal drug transporters remains to be elucidated. We aimed to quantify the effect of inflammation (caused by acute pyelonephritis) on the in vivo activity of renal OAT1/3, using the probe drug furosemide. Pregnant women (2nd or 3rd trimester) received a single oral dose of furosemide 40 mg during acute pyelonephritis (Phase 1; n = 7) and after its resolution (Phase 2; n = 7; by treatment with intravenous cefuroxime 750 mg TID for 3-7 days), separated by 10 to 14 days. IL-6, IFN-γ, TNF-α, MCP-1, and C-reactive protein plasma concentrations were higher in Phase I vs Phase II. The pregnant women had a lower geometric mean [CV%] furosemide CLsecretion (3.9 [43.4] vs 6.7 [43.8] L/h) and formation clearance to the glucuronide (1.1 [85.9] vs 2.3 [64.1] L/h) in Phase 1 vs. Phase 2. Inflammation reduced the in vivo activity of renal OAT1/3 (mediating furosemide CLsecretion) and UGT1A9/1A1 (mediating the formation of furosemide glucuronide) by approximately 40% and 54%, respectively, presumably by elevating plasma cytokine concentrations. The dosing regimens of narrow therapeutic window OAT drug substrates may need to be adjusted during inflammatory conditions.